Martínez PY, Abdel YA, Abreu GMR

Language: Spanish
References: 28
Page: 69-82
PDF size: 135.59 Kb.

ABSTRACT

In the natural history of hepatic cirrhosis, approximately the 50 % of patients has its first decompensation as a ascites way, which at its turn, if it not appropriately treated may leads to other complications more severe such that spontaneous bacterial peritonitis and other, perhaps irreversible including the hepatorenal syndrome. About the 60 % of patients with compensated cirrhosis develops ascites during the first 10 years after diagnosis. This matter was reviewed to decrease the figure of complications and deaths due to this cause.

REFERENCES

1. Runyou BA. AASLD Practice guidelines committee. Management of adult patients with ascites due to cirrhosis: an up date. Hepatology. 2009;49(6):2087-107.

2. Salermo F, Camma C, Enea M, Rossie M, Wong F. Transyugular intrahepatic portosystemic shunt for refractory ascites: a meta analysis of individual patient data. Gastroenterology. 2007;133:825-34.

3. Singh V, Dheerendra PC, Singh B. Midridines versus albumin in the prevention of paracentesis-induce circulatory dysfunction in the cirrotics: a randomized pilot study. Am J Gastroenterology. 2008;103:1399-405.

4. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure. Part I: Diagnosis and evaluation. Am Fam Physician. 2006;74:756-62.

5. Gines P, Wong F, Watson M, Ruiz-Del-Arbol L, Bilic A, Dobru D. Effects of satavanptan, a selective vasopressin V2 receptor antagonist, on ascites and serum in cirrhosis with hiponatremia. Hepatology. 2008;48:204-13.

6. Gines P, Wong H, Terg R, Brua R, Zarski P. Clinical trial: short term effects of combination of satavaptan, a selective vasopressin V receptor antagonist, and diurects on ascites in patients witch cirrhosis without hypernatremia- a randomized double blind placebo controlled study. Aliment Pharmacol Ther. 2010;31:834-45.

7. Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, et al. Effect of a selective vasopressin V2 recpetor antagonist, satavaptan, on ascites recurrence after paracentesis in patients in patients with cirrhosis. J Hepatol. 2010;53:283-90.

8. Wong F, Bernardi M, Horsmans Y, Cabrijan z, Watson H, Gies P. Effects of satavaptan, an oral vasopressin v2 receptor antagonist, on management of ascites and mosbidity in liver cirrhosis i a long-terms, placebo-controlled study. J Hepatol. 2009;50:542-3.

9. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure. Part II: Complications and treatment. Am Fam Physician. 2006;776579.

10. Fosolato S, Angeli P, Dallagnese l, Maresio G Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical feature. Hepatology. 2007;45:223-9.

11. Heidelbaugh Joel J, Sherbondy M. University of Michigan Medical School, Ann Arbor, Michigan. Cirrhosis and Chronic Liver Failure: Part II. Complications and Treatment. Am Fam Physician. 2006 Sep 1;74(5):767-76.

12. Salerno F, Gerbes A, Gine SP. Wong F, Vicente A. American Association for the Study of Liver Disease. Diagnóstico, prevención y tratamiento del síndrome hepatorrenal en la cirrosis. Gut. 2007;65:1310-8.

13. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Muñoz A, et al. Serum creatinine and bilirrubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int. 2009;29:415-9.

14. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebocontrolled study. J Hepatol. 2008;48:774-9.

15. Hyponatremia treatment guidelines 2007. Expert panel recommendations. Am J Med. 2007;120:51-2.

16. Dawas MF, Lewsey JD, Neuberger J. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115-1124.

17. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:208710.

18. Appenrodt B, Wolf A, Grunhage F. Prevention of paracentesis induced circulatory dysfunction: midodrine versus albumin. A randomized pilot study. Liver Int. 2008;28:101925.

19. De Gottardi A, Thevenot T, Spahr L. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7:9069.

20. Salerno F, Merli M, Riggio O. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:62935.

21. D'Amico G, Luca A, Morabito A. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129:1282-93.

22. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.

23. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69 2124-30.

24. Decaux G, Soupart A, Vassart G. Non-peptide argininevasopressin antagonists: the vaptans. Lancet. 2008;371:1624-32.

25. Castellote J, Girbau A, Maisterra S. Spontaneous bacterial peritonitis and bacterascites prevalencein symptomatic cirrhotic outpatients undergoing large volume paracentesis. J Gastroenterol Hepatol. 2008;23:2569.

26. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42:S8592.

27. Fernández J, Navasa M, Planas R. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-24.

28. Gerbes AL, Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology. 2005;41:217.